Investigation of the promising repurposed, computational, and anticancer candidates to co-deliver with cabazitaxel for hormonal-resistance prostate cancer
The novel antimicrotubular taxane called cabazitaxel was developed to avoid the primary mechanism of resistance for docetaxel, the first-line treatment for patients with hormone-resistant prostate cancer (HRPC).However, its ability to increase the survival rate for HRPC is limited to a few months, and cabazitaxel-resistant prostate cancer was also